 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Efficacy of temozolomide combined with radiotherapy vs radiotherapy alone in IDH wild-type glioblastoma

Clin Cancer Res: Efficacy of temozolomide combined with radiotherapy vs radiotherapy alone in IDH wild-type glioblastoma

 Last Update: 2022-04-22
 Source: Internet
 Author: User

Tags

influenza survival rate

combination therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In 2005, the randomized EORTC 26981/22981-NCIC CE3 trial demonstrated for the first time the clinical benefit of adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma
.

Other studies have confirmed that elderly patients with glioblastoma can also benefit from temozolomide combined with radiotherapy

Here, we report a post hoc analysis of the CATNON trial of whether adjuvant radiation therapy combined with temozolomide improves outcomes in patients with anaplastic astrocytoma without IDH1/2 mutations with molecular features of glioblastoma
.

Does adjuvant radiotherapy combined with temozolomide improve outcomes in patients with anaplastic astrocytoma without IDH1/2 mutations with molecular features of glioblastoma

The CATNON trial was a randomized phase 3 study to investigate the effect of adjunctive or concurrent use of temozolomide during radiotherapy in patients with anaplastic astrocytoma
.

The analysis included IDH1/2 wild-type and H3F3A wild-type patients, and subgroup analysis was performed according to the presence or absence of TERT promoter mutation and/or EGFR amplification and/or chromosome 7 gain and/or chromosome 10 deletion

Overall survival in both groups

Of the 751 patients enrolled in the CATNON trial, 670 had complete molecular characterization information, of which 159 met molecular criteria for IDH wild-type glioblastoma
.

Of these patients, 47 received radiotherapy alone and 112 received radiotherapy in combination with temozolomide

Compared with the radiotherapy group, the overall survival rate and progression-free survival rate of the combination therapy group were not significantly improved .

Progression-free survival in both groups

MGMT promoter methylation had a prognostic effect on overall survival in patients tested , but not in overall survival and progression-free survival in patients treated with temozolomide
.

MGMT promoter methylation has a prognostic effect on the overall survival of the test patients MGMT promoter methylation has a prognostic effect on the overall survival of the test patients

In conclusion, in a cohort of patients with IDH wild-type glioblastoma, temozolomide treatment did not further improve clinical outcomes in addition to radiotherapy , regardless of MGMT promoter status
.

The findings of this study require further validation

Temozolomide treatment does not further improve the clinical prognosis of patients on the basis of radiotherapyTemozolomide treatment does not further improve the clinical prognosis of patients on the basis of radiotherapy

Original source:

Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.